SCHEMBL30474183

SCHEMBL30474183

Cc1ccc(CBr)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
PYCR1 P32322 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2A6 P11509 1/20 0.35
MAPK1 P28482 3/20 0.34
CYP2C19 P33261 3/20 0.34
CYP2C9 P11712 2/20 0.34
CYP3A4 P08684 2/20 0.34
LMNA P02545 1/20 0.34
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
HPGD P15428 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16998685 1.00 IDO1 (0.35) IDO1KMT2ANPSR1MAPTL3MBTL1
SCHEMBL16998686 0.82 HTR2A (0.41) KMT2ANPSR1MAPTL3MBTL1ALDH1A1
SCHEMBL30707192 0.82 HTR2A (0.41) KMT2ANPSR1MAPTL3MBTL1ALDH1A1
SCHEMBL13932525 0.81 AMY1A (0.42) IDO1KMT2ANPSR1MAPTL3MBTL1
SCHEMBL2355598 0.81 TAAR1 (0.40) IDO1KMT2ANPSR1MAPTL3MBTL1
SCHEMBL29393025 0.79 KMT2A (0.48) IDO1KMT2ANPSR1MAPTL3MBTL1
SCHEMBL30345107 0.79 PYCR1 (0.47) IDO1KMT2APYCR1ALDH1A1CYP1A2
SCHEMBL307792 0.79 PYCR1 (0.47) IDO1KMT2APYCR1ALDH1A1CYP1A2
SCHEMBL8230054 0.79 GRIN2D (0.41) IDO1KMT2ANPSR1MAPTL3MBTL1
SCHEMBL7039692 0.79 KMT2A (0.48) IDO1KMT2ANPSR1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 EP disclosed
WO-2024199444-A1 HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海翊维康医药有限责任公司 2024-10-03 WO disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR IDO1 2085/4885KMT2A 3670/4885NPSR1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.